While other pharmaceutical companies are competing with each other for weight loss products and thus pushing margins down.
I will simply remain invested in Vertex.
Morgan Stanley upgraded Vertex Pharmaceuticals (NASDAQ:VRTX) from "Equalweight" to "Overweight" on Wednesday and raised the price target from USD 438.00 to USD 516.00. The new target implies an upside potential of around 19% from the current price of USD 433.15.
The upgrade reflects Morgan Stanley's more positive view on Vertex's renal pipeline. In particular, it emphasizes the potential of the two drug candidates Pove and Inaxaplin, for which data from Phase 3 clinical trials are expected in 2026. This optimism is in line with broader analyst sentiment, as InvestingPro data shows that 18 analysts have recently revised their earnings estimates upwards for the coming period.
Morgan Stanley predicts that successful development of these renal drugs would accelerate Vertex's diversification beyond its core cystic fibrosis business. This segment currently accounts for 98% of sales, but this share is expected to fall to 49% by 2035.
The investment bank expects a compound annual growth rate (CAGR) of around 8% in sales and 10% in earnings per share for the period from 2025 to 2035. The new price target implies a price/earnings (P/E) ratio of 27 based on earnings estimates for 2026 and 26 for 2027.
While Morgan Stanley acknowledges slowing growth in Vertex's cystic fibrosis division, it points out that patent protection extends into the late 2030s and there are only minimal competitive risks. This gives the company time to expand its portfolio beyond this therapeutic area. Despite these challenges, according to InvestingPro's Financial Health Check, Vertex is in strong financial shape with an overall rating of 3.09 ("GREAT"), supported by robust sales growth of 10.33% over the last twelve months.
Most recently, Vertex Pharmaceuticals also reported promising 48-week data for its experimental therapy povetacicept in two severe kidney diseases. The data showed a significant reduction in proteinuria and stabilization of renal function, with a 64% reduction in patients with IgA nephropathy and 82% reduction in patients with primary membranous nephropathy. At the same time, the company exceeded earnings expectations with 21 cents per share, due to strong sales of Trikafta and lower taxes. However, sales were only in line with guidance and the performance of newer products was mixed, according to Cantor Fitzgerald, which maintained its Overweight rating and $485 price target.
